Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-111077 + Decitabine + Venetoclax in AML
NCT03063944Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPB-111077 in acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of grade 4, non-hematologic dose limiting toxicities up to 2 years. Started Mar 2017; status: completed.
02
Drugs
OPB-111077
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03063944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063944.